Navigation Links
Vet-Stem, Inc. Founder and CEO, Robert Harman, DVM, Presents at Prestigious Stem Cell Conference at Case Western Reserve University
Date:7/18/2013

Poway, CA (PRWEB) July 18, 2013

Vet-Stem, Inc., a biotechnology company that develops and markets revolutionary products in the field of Veterinary Regenerative MedicineTM, announced that Chief Executive Officer Robert J. Harman, DVM presented this week at the Case Western Reserve University meeting “The Business of Regenerative Medicine: From Stem Cells to the Market Place” in Cleveland, Ohio. Dr. Harman has been a regular presenter at this prestigious meeting, providing insights into the commercialization of stem cell technology in the veterinary field.

Dr. Harman spoke as part of the New Leadership in Regenerative Medicine Session describing the outcomes and business metrics from more than 10,000 horse, dog and cat patients treated over the last 10 years in both the U.S. and Canada using proprietary Vet-Stem technology. Dr. Harman, the only presenter from the veterinary field, presented along with more than 20 other leading companies in the regenerative medicine field. The CEOs of OSIRIS, BioTime, Mesoblast and the Directors of the Harvard Stem Cell Institute, and Genetics Policy Institute, along with many other global leaders also spoke.

Arnold I. Caplan, PhD, the meeting organizer and technology pioneer in cell-based therapies in Regenerative Medicine, is a scientific advisor to Vet-Stem, Inc.

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.’s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10940351.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Former COO and CSO of IDEXX Laboratories, Inc. Joins Board of Directors for Vet-Stem, Inc.
2. GenoSpace Founder and CEO Receives "Champions of Change" Award from White House
3. Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013
4. Future of Pre- and Probiotics to be Discussed by Kibow Biotech Founder During SupplySide MarketPlace 2013 Global Expo & Conference
5. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair
6. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
7. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
8. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
9. Robert Sullivan, PhD, Dean of Rady School Of Management, to Join Stemedica Board of Business Advisors
10. Robert Lowen MD, Expert Bay Area Plastic Surgeon, Announces Cutting-Edge 3-D Crisalix Imaging Technology to Aid Patients in Choosing their Breast Implant Size
11. Dr. J. Robert Beyster and Betty J. Beyster Make $2.5 Million Pledge to the J. Craig Venter Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):